Comparison of Performances of Adalimumab Biosimilars SB5, APB501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Antonio TursiGiammarco MocciLeonardo AllegrettaGiovanni AragonaMaria Antonia BiancoRaffaele ColucciAntonio CuomoNicola Della ValleAntonio FerronatoGiacomo FortiFederica GaianiGianMarco GiorgettiMaria Giovanna GrazianiKatia LofanoRoberto LorenzettiTiziana LarussaAntonio PennaRoberta PicaGiuseppe PranzoStefano Rodino'Antonella ScarcelliCostantino ZampalettaGabrio BassottiAlessia Immacolata CazzatoStefania ChiriValeria ClementeAndrea CoccoGianluigi De' AngelisLaura DonnarummaRoberto FaggianiCamilla GraziosiMarco Le GrazieFrancesco LuzzaCostantino MeucciRita MonterubbianesiCristiano PagniniPatrizia PerazzoMarcello PicchioRodolfo SaccoLadislava SebkovaMariaelena SerioDaniele NapolitanoDaniela PuglieseFranco ScaldaferriElisa SchiavoniLaura TurchiniAlessandro ArmuzziWalter EliseiGiovanni MaconiAlfredo PapaPublished in: Inflammatory bowel diseases (2022)
Adalimumab biosimilars are effective and safe in IBD treatment, both in new patients and in patients switched from the ADA originator. No difference in efficacy and safety was found between ADA biosimilars.